Barclays raised the firm’s price target on BioMarin (BMRN) to $105 from $80 and keeps an Overweight rating on the shares. The firm updated the company’s model to include Amicus and the Voxzogo indication expansion. It sees both as key value drivers for the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN: